Lexington Medical Center

Lexington Medical Center
2720 Sunset Blvd.
West Columbia, SC 29169

Taylor Knight, Research Coordinator: tvknight@lexhealth.org
Selena Lollar, Research Coordinator: swlollar@lexhealth.org
Kate Madden, Research Coordinator: kdmadden@lexhealth.org

National Cancer Institute Community Oncology Research Program logo

As an affiliate of the Medical University of South Carolina, Lexington Medical Center is an active Minority/Underserved NCORP site. Lexington Medical Center is currently active on the following clinical trials addressing various cancer types. Ask your health care provider for more information.


  • A011801: The CompassHER2 Trials (Comprehensive Use of Pathological Response Assessment to Optimize Therapy in HER2 Positive Breast Cancer): CompassHer2 Residual Disease (RD), A Double Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
    This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2-positive breast cancer.
    Trial Details
  • CCTG MA.39: Testing regional radiation therapy in patients with low risk breast cancer
    This trial studies if not giving regional radiotherapy is just as good as using regional radiotherapy in keeping breast cancer from coming back in patients with estrogen receptor-positive, HER2-negative, node-positive low-risk breast cancer who have undergone breast conserving surgery or mastectomy.
    Trial Details

Genitourinary — Prostate

  • EA8184: A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
    This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.
    Trial Details


  • A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery.
    Trial Details

Thoracic — Lung

  • A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
    The purpose of this screening trial is to centrally genotype resected lung adenocarcinomas for EGFR mutations and ALK rearrangements to facilitate accrual to randomized adjuvant studies.
    Trial Details
  • A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo IO
    This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.
    Trial Details
  • E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
    This phase III trial will evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) over placebo for patients with stage IB, II and IIIA, ALK-positive NSCLC following surgical resection.
    Trial Details